Zelira Therapeutics, a company that commercializes clinically validated cannabinoid medicines, launches ZYRAYDI™, its patented, licensable technology for the medical cannabis industry.
ZYRAYDI™ is a proprietary Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology designed to trap the distillate in a free-flow powder matrix and increase the rate of dissolution. The ZYRAYDI matrix contains pharmaceutical-grade excipients that are on the FDA-approved list of GRAS (Generally Recognized As Safe) ingredients, and can be adapted to fit requirements for vegan, gluten-free, allergen-free, non-GMO and other drug delivery forms.